CoChat

Invasive Fungal Disease Complicating Coronavirus Disease 2019: When It Rains, It Spores

Open access
Hoenigl, Martin · 2021 · Clinical Infectious Diseases
Cited by 125

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

(See the Major Article by White et al on pages e1634–44.) A century ago, the 1918 influenza pandemic changed the world, when one-third of the world’s population became infected and >50 million people died. By examining lung tissue samples preserved in paraffin blocks, Morens and colleagues from the National Institute of Allergy and Infectious Diseases found only out 80 years later that in fact the majority of deaths in the 1918 influenza pandemic resulted not from viral pneumonia, but from secondary bacterial pneumonia caused by common upper respiratory tract bacteria [1]. Now we are facing another devastating worldwide pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with to date >24 million individuals infected and a mortality rate >3%. Although superinfections were rarely reported in the beginning of the current pandemic, they are now on the rise, particularly reports about secondary fungal disease. SARS-CoV-2–associated pulmonary aspergillosis (CAPA) has been the predominant fungal disease, adding insult to injury in coronavirus disease 2019 (COVID-19) patients with acute respiratory distress syndrome (ARDS), and although the pathogenesis is incompletely understood, there are several immunological mechanisms that may contribute to the development of CAPA and other fungal diseases. SARS-CoV-2 invasion results in the release of danger-associated molecular patterns (DAMPs) that act as endogenous signals that exacerbate the immune and inflammatory response leading to lung injury [2, 3]. Importantly, DAMPs are known to play a central role in the pathogenesis of fungal diseases [4]. Moreover, collateral effects of host recognition pathways required for the activation of antiviral immunity may, paradoxically, contribute to a highly permissive inflammatory environment that favors fungal pathogenesis [2]. To date, >100 cases of CAPA have been reported from many countries in Europe, Asia, Australia, and South America [2, 5–18], often occurring in patients with no other risk factor than COVID-19–associated ARDS [2], and multiple of them proven by autopsy [17, 19, 20]. In contrast, there are fewer reports on other fungal diseases complicating COVID-19, including 2 cases of Saccharomyces cerevisiae fungemia caused by fungal translocation [21] after administration of probiotic preparations containing Saccharomyces [22], cases of invasive Candida infections [23], and a case of invasive fusariosis [24]. Now, in this issue of Clinical Infectious Diseases, White and colleagues from the United Kingdom report a 26.7% incidence of invasive fungal disease in a multicenter prospective cohort of COVID-19 intensive care patients, including a 12.6% incidence of invasive yeast infections [25]. CAPA still accounted for the majority of fungal disease cases (14% of the cohort), although this was lower than the average incidence rate of 26% reported in previous studies. Of note, CAPA incidence rates reported to date have varied widely, ranging from 4% [15] to 35% [19] in mechanically ventilated critically ill patients. Factors that may contribute to the differing incidence rates are 3-fold. First, fungal diseases and specifically CAPA are difficult to diagnose and are likely underestimated, particularly in the setting of COVID-19–associated ARDS, where the clinical picture and radiological findings of CAPA resemble those of severe COVID-19 [7, 26]; blood tests lack sensitivity due to the primarily airway invasive growth of Aspergillus in nonneutropenic patients [27]; and, most importantly, sampling of the primary site of infection is rarely performed, due to the risk of COVID-19 transmission through bronchoscopies with bronchoalveolar lavage (BAL) or autopsies (due to the overlap of imaging findings between CAPA and COVID-19, postmortem fine needle biopsies alone may not be sufficient to detect focal CAPA [28]), which are both aerosol-creating procedures [29]. Random diagnosis of CAPA, without specifically and creatively searching for it, is therefore virtually impossible in this setting, and diagnosis requires specific expertise and awareness, which is rare given that fungi are neglected pathogens [30, 31]. Also, in many places around the world, clinical mycology remains a neglected subspecialty in the medical field, sometimes overlooked even within the specialty of infectious diseases where the focus is often laid on more common bacterial and viral infections. Funding for research on fungal diseases is limited compared to funding available for other infectious diseases that cause similar or lower mortality, a fact that is outlined by the Global Funding of Innovation for Neglected Diseases (G-Finder) Report [31]. Second, screening of critically ill COVID-19 patients for CAPA is necessary but serum galactomannan (GM), the screening standard in other high-risk settings, has limited utility because of a low sensitivity of only 21% for CAPA [2]. Screening with serum (1–3)-ß-D-glucan (BDG) might show bette

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciaa1342

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 125

Metadata

Authors
Hoenigl, M.
Venue
Clinical Infectious Diseases
Published
2020-09-05
Volume
73
Issue
7
Pages
e1645-e1648
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W3081584250
Cited by
125
References
8
FWCI
3.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Invasive Fungal Disease Complicating Coronavirus Disease 2019: When It Rains, It Spores. https://app.cochat.ai/papers/10.1093/cid/ciaa1342
The paper
Hoenigl, M. (2021). Invasive Fungal Disease Complicating Coronavirus Disease 2019: When It Rains, It Spores. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa1342

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.